Literature DB >> 329521

Malignancies associated with renal transplantation.

I Penn.   

Abstract

An increased incidence of cancer occurs in renal homograft recipients. Malignancies may be inadvertently transplanted with the kidney from donors with cancer, or may arise de novo at some time after transplantation. The latter tumors occur on an average of thirty-four months after the operation. The most common tumors are carcinomas of the skin and lip, lymphomas (mostly reticulum cell sarcomas), and carcinomas of the cervix of the uterus. The lymphomas have a marked predilection for the central nervous system. Besides conventional cancer therapy, reduction or cessation of immunosuppression may be warranted. The development of malignancies is not a contraindication to renal transplantation since the over-all death rate from cancer in kidney homograft recipients is low.

Entities:  

Mesh:

Year:  1977        PMID: 329521

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Pregnancy complicated by gestational trophoblastic disease in a renal transplant recipient.

Authors:  I H Manifold; A E Champion; J R Goepel; S Rameswak; P E Mayor
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-08

2.  Principal neuropathological and general necropsy findings in 24 renal transplant patients.

Authors:  R Morton; D I Graham; J D Briggs; D N Hamilton
Journal:  J Clin Pathol       Date:  1982-01       Impact factor: 3.411

3.  Lymphomatoid granulomatosis involving the central nervous system: complication of a renal transplant with terminal monoclonal B-cell proliferation.

Authors:  J Michaud; D Banerjee; J C Kaufmann
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

4.  Risk Factors of Graft Survival After Diagnosis of Post-kidney Transplant Malignancy: Using Cox Proportional Hazard Model.

Authors:  Abbas Rahimi Foroushani; Mahmoud Salesi; Zohreh Rostami; Ali Reza Mehrazmay; Jamile Mohammadi; Behzad Einollahi; Mohammad Reza Eshraghian
Journal:  Iran Red Crescent Med J       Date:  2015-11-14       Impact factor: 0.611

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.